Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
about
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanomaPhase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.Malignant melanoma (metastatic)Initial testing (stage 1) of temozolomide by the pediatric preclinical testing programEfficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: a meta-analysis.Systematic review of medical treatment in melanoma: current status and future prospects.The anti-angiogenic basis of metronomic chemotherapy.New advances on the functions of epidermal growth factor receptor and ceramides in skin cell differentiation, disorders and cancers.Thalidomide and immunomodulatory drugs in the treatment of cancer.Immunomodulatory drugs.Chemotherapy for metastatic melanoma.Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations.Temozolomide for the treatment of metastatic melanomaMolecular-targeted therapy in malignant melanoma.Diagnosis and treatment of melanoma brain metastasis: a literature review.Inhibition of angiogenesis for the treatment of metastatic melanoma.Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo.Postoperative DAV-IFN-β therapy does not improve survival rates of stage II and stage III melanoma patients significantly.A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours.Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.Antiangiogenic therapy for primitive neuroectodermal tumor with thalidomide: A case report and review of literature.Malignant melanoma (metastatic).Targeting angiogenesis in melanoma
P2860
Q24246409-DFB2DA0F-3D90-4F0C-8D54-8C72BCF3FEBCQ33611998-3E1DFB84-6F52-40EB-9D7F-7978E4F93ABDQ33850507-0BC722D0-2A46-4FBE-9980-2BA9A1D18BF7Q34571940-460A0C92-17D5-4CD3-BCF4-468D311C1A33Q35026931-4209DEAC-8699-4400-9AD0-65F08401D6B4Q35584299-A08C394F-8BAC-4F67-81C9-BAC84EFFCB4CQ35788112-C94DD546-BB06-486D-A434-6365F1134125Q35838744-DBABE448-1834-4F07-900B-0A75AD6713E3Q36040871-1F0AF6BD-FC48-4E18-8E11-A8E836AF9737Q36321396-B5034917-D081-41FB-8D6B-6898F914902CQ36352095-56555960-90D5-4B46-91D2-9A5E7AF582CFQ36616482-61FD2EA6-EE91-4B95-ABB9-399DF2741172Q36852256-5DD8D137-3A5D-42E2-B756-AC5E26E6B073Q37483949-64A38D57-6332-4E1C-A90E-DF4D6DADF402Q37531863-9E03D6CF-176E-4672-94AA-355A9EA9EA55Q38134302-EF0D4579-06C2-48C1-B856-5F5C23AB734EQ38917853-4BF01255-B93B-4293-A8CB-F51142BA0697Q39591407-F40B2436-E703-4FE5-8C14-AA511F2C9D40Q44248810-C9CF5908-D6C8-40DB-8FD3-920FD8A83131Q44902310-F1BE35DE-5430-46D8-B6AE-5E9064351242Q48567066-48B96681-FD8D-427B-9B70-51986C79B094Q49452336-7A5308FB-0A5F-4E8F-9561-317AA600DF96Q55549078-34FCA046-9588-4D6A-A439-9229A1DE9FAAQ57569703-30A3C4C1-2AA8-4082-B76F-E7572417F48B
P2860
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Randomized phase II study of t ...... metastatic malignant melanoma.
@en
type
label
Randomized phase II study of t ...... metastatic malignant melanoma.
@en
prefLabel
Randomized phase II study of t ...... metastatic malignant melanoma.
@en
P2093
P356
P1476
Randomized phase II study of t ...... metastatic malignant melanoma.
@en
P2093
J Hodgetts
L Ashcroft
M R Middleton
N Thatcher
P304
P356
10.1200/JCO.2003.10.039
P407
P577
2003-07-01T00:00:00Z